Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pain Therapeutics Sees Potential Hemophilia Cure Entering Clinic In 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

Gene integration technology would mean “once-a-lifetime treatment,” CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Wyeth’s Xyntha Wins FDA Nod For Hemophilia A

Factor VIII is made by modifying genes from Chinese hamster ovary cells to reduce infection risk.

Wyeth’s Xyntha Wins FDA Nod For Hemophilia A

Factor VIII is made by modifying genes from Chinese hamster ovary cells to reduce infection risk.

Pain Therapeutics Ends Year Flush, “Slightly Ahead” Of Alpharma

Abuse-deterrent pain drug market big enough for all, analyst tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS065804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel